XML 28 R21.htm IDEA: XBRL DOCUMENT v3.25.2
Summary of Significant Accounting Policies (Tables)
6 Months Ended
Jun. 30, 2025
Accounting Policies [Abstract]  
Schedule of Segment Reporting

 

 

For the Three Months
Ended June 30,

 

 

For the Six Months
Ended June 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Tegoprubart - kidney transplantation programs

 

$

8,705

 

 

$

4,620

 

 

$

17,237

 

 

$

9,117

 

Tegoprubart - other development programs

 

 

 

 

 

345

 

 

 

(168

)

 

 

416

 

Manufacturing

 

 

7,626

 

 

 

2,797

 

 

 

9,295

 

 

 

3,574

 

Personnel-related

 

 

3,697

 

 

 

2,350

 

 

 

7,144

 

 

 

4,875

 

Stock-based compensation

 

 

2,694

 

 

 

3,063

 

 

 

5,558

 

 

 

4,757

 

Other operating expenses

 

 

2,011

 

 

 

1,327

 

 

 

3,631

 

 

 

2,632

 

Total operating expenses

 

 

24,733

 

 

 

14,502

 

 

 

42,697

 

 

 

25,371

 

Loss from operations

 

 

(24,733

)

 

 

(14,502

)

 

 

(42,697

)

 

 

(25,371

)

Other income, net

 

 

1,224

 

 

 

869

 

 

 

2,633

 

 

 

1,443

 

Change in fair value of warrant liabilities

 

 

12,293

 

 

 

(31,274

)

 

 

22,353

 

 

 

(44,610

)

Segment and net loss

 

$

(11,216

)

 

$

(44,907

)

 

$

(17,711

)

 

$

(68,538

)